Rachael C. Natrajan
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 73 publications
Co-occurrence of transcriptionally distinct persister cell states underpins neoadjuvant therapy resistance in triple‑negative breast cancer.
Journal: Genome medicine
Published: November 14, 2025
Proteogenomic discovery of RB1-defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets.
Journal: Science advances
Published: March 26, 2025
Clinical challenges and proposed solutions for patients with invasive lobular breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 22, 2024
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.
Journal: Oncogene
Published: June 17, 2024
Dysregulated SASS6 expression promotes increased ciliogenesis and cell invasion phenotypes.
Journal: Life science alliance
Published: May 13, 2024
Basal-epithelial subpopulations underlie and predict chemotherapy resistance in triple-negative breast cancer.
Journal: EMBO molecular medicine
Published: November 11, 2023
Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer.
Journal: British journal of cancer
Published: June 02, 2023
Implications of tumour heterogeneity on cancer evolution and therapy resistance: lessons from breast cancer.
Journal: The Journal of pathology
Published: May 22, 2023
Evolutionary determinants of curability in cancer.
Journal: Nature ecology & evolution
Published: January 23, 2023
Definitive study shows no association between ARID1A mutation status and clinical outcome in endometriosis-related ovarian cancers‡.
Journal: The Journal of pathology
Published: May 04, 2022
Characterisation of the Stromal Microenvironment in Lobular Breast Cancer.
Journal: Cancers
Published: December 22, 2021
Last Updated: 09/26/2026